Entering text into the input field will update the search result below

MoonLake Immunotherapeutics initiated with an Outperform at Cowen

Jul. 07, 2022 1:46 PM ETMLTXBy: Pranav Ghumatkar, SA News Editor
  • Cowen analyst Phil Nadeau initiated coverage of MoonLake Immunotherapeutics (MLTX) with an Outperform rating.
  • The company is developing sonelokimab in inflammatory diseases and Phase 2 data in psoriasis suggest improved safety and efficacy compared to traditional anti-IL-17A/F monoclonal antibodies, Nadeau tells investors.
  • He expects the company to create shareholder value as sonelokimab advances.
  • Since the start of 2022, MoonLake Immunotherapeutics's shares were down around 42%, and over a period of one year, shares were down around 44%.
  • Shares are currently +2.33% to $5.71 today.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.